2 May 2019

Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin (HSA).

Pursuant to the terms of the licensing agreement, CStone will fund the research and development of ND021 up to completion of an initial Phase Ib clinical trial. In exchange, CStone obtains exclusive rights from Numab to develop and commercialize ND021 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan), South Korea and Singapore. Numab retains all ND021 rights for the rest of the world. Upon completion of CStone’s funding period, no further financial obligations will be owed by either party. This collaboration provides CStone with its first access to Numab’s novel multi-specific technology platform and Numab the opportunity to bring this innovative drug candidate into this region.

Press Release Numab

VISCHER advises Numab in this transaction. The VISCHER team is led by Stefan Kohler (Partner, Life Sciences & IP) and Christoph Niederer (Partner, Tax).

Categories: China Desk, Intellectual Property, Life Sciences, Pharma, Biotech, Public Sector & Regulatory, Tax

You are currently offline. Some pages or content may fail to load.